Аполихин О.И., Сивков А.В., Комарова В.А. и др. Заболеваемость мочекаменной болезнью в Российской Федерации (2005–2016 годы). Экспериментальная и клиническая урология 2018;(4):4–14.
D’Costa M.R., Haley W.E., Mara K.C. et al. Symptomatic and radiographic manifestations of kidney stone recurrence and their prediction by risk factors: a prospective cohort study. J Am Soc Nephrol 2019;30(7):1251–60.
DOI: 10.1681/ASN.2018121241
Robertson W.G. Stone formation in the Middle Eastern Gulf States: a review. Arab J Urol 2012;10(3):265–72.
DOI: 10.1016/j.aju.2012.04.003
Medina-Escobedo M., Sánchez-Pozos K., Gutiérrez-Solis A.L. et al. Recurrence of nephrolithiasis and surgical events are associated with chronic kidney disease in adult patients. Medicina (Kaunas) 2022;58(3):420.
DOI: 10.3390/medicina58030420
Алфимов А.Е., Шадеркин И.А., Лебедев Г.С. и др. Мочекаменная болезнь и риск инфаркта миокарда и инсульта. Экспериментальная и клиническая урология 2022;15(2)74–86.
DOI: 10.29188/2222-8543-2022-15-2-74-86
Robertson W.G. A risk factor model of stone-formation. Front Biosci 2003;8:s1330–8.
DOI: 10.2741/1181
Hallson P.C., Rose G.A. A new urinary test for stone “activity”. Br J Urol 1978;50(7):442–8.
DOI: 10.1111/j.1464-410x.1978.tb06188.x
Шатохина С.Н., Шабалин В.Н. Ранняя диагностика уролитиаза, определение степени его активности и состава камнеобразующих солей мочи (система Литос). Урология и нефрология 1998;1:19–23.
Grases F., García-Ferragut L., Costa-Bauzá A. et al. Simple test to evaluate the risk of urinary calcium stone formation. Clin Chim Acta 1997;263(1):43 –55.
DOI: 10.1016/s0009-8981(97)06554-6
Yang B., Dissayabutra T., Ungjaroenwathana W. et al. Calcium oxalate crystallization index (COCI): an alternative method for distinguishing nephrolithiasis patients from healthy individuals. Ann Clin Lab Sci 2014;44(3):262–71
More-Krong P., Tubsaeng P., Madared N. et al. Clinical validation of urinary indole-reacted calcium oxalate crystallization index (iCOCI) test for diagnosing calcium oxalate urolithiasis. Sci Rep 2020;10(1):8334.
DOI: 10.1038/s41598-020-65244-1
Laube N., Berg W., Bernsmann F. et al. Induced urinary crystal formation as an analytical strategy for the prediction and monitoring of urolithiasis and other metabolism-related disorders. EPMA J 2014;5(1):13.
DOI: 10.1186/1878-5085-5-13
Porowski T., Kirejczyk J.K., Mrozek P. et al. Upper metastable limit osmolality of urine as a predictor of kidney stone formation in children. Urolithiasis 2019;47(2):155–63.
DOI: 10.1007/s00240-018-1041-2
Nicar M.J., Hill K., Pak C.Y. A simple technique for assessing the propensity for crystallization of calcium oxalate and brushite in urine from the increment in oxalate or calcium necessary to elicit precipitation. Metabolism 1983;32(9):906–10.
DOI: 10.1016/0026-0495(83)90205-6
Tiselius H.G. Measurement of the risk of calcium phosphate crystallization in urine. Urol Res 1987;15(2):79–81.
DOI: 10.1007/BF00260937
Ulmann A.. Nephrologie 1984;5(5):232–4
Hsi R.S., Sanford T., Goldfarb D.S., Stoller M.L. The role of the 24-hour urine collection in the prevention of kidney stone recurrence. J Urol 2017;197(4):1084–9.
DOI: 10.1016/j.juro.2016.10.052
Curhan G.C., Willett W.C., Speizer F.E., Stampfer M.J. Twenty-four-hour urine chemistries and the risk of kidney stones among women and men. Kidney Int 2001;59(6):2290–8.
DOI: 10.1046/j.1523-1755.2001.00746.x
Sutton R.A. The use of risk indices: do they predict recurrence? Urol Res 2006;34(2):122–5.
DOI: 10.1007/s00240-005-0023-3
Sikora P., Zajaczkowska M., Hoppe B. Assessment of crystallization risk formulas in pediatric calcium stone-formers. Pediatr Nephrol 2009;24(10):1997–2003.
DOI: 10.1007/s00467-009-1167-0
Rodriguez A., Cunha T.D.S., Rodgers A.L. et al. Comparison of supersaturation outputs from different programs and their application in testing correspondence with kidney stone composition. J Endourol 2021;35(5):687–94.
DOI: 10.1089/end.2020.0894
Robertson W.G. Methods for diagnosing the risk factors of stone formation. Arab J Urol 2012;10(3):250–7.
DOI: 10.1016/j.aju.2012.03.006
Marangella M., Petrarulo M., Vitale C. et al. LITHORISK.COM: the novel version of a software for calculating and visualizing the risk of renal stone. Urolithiasis 2021;49(3):211–7.
DOI: 10.1007/s00240-020-01228-0
Tiselius H.G. Risk formulas in calcium oxalate urolithiasis. World J Urol 1997;15(3):176–85.
DOI: 10.1007/BF02201855
Söhnel O., Grases F. Urinary supersaturation as a diagnostic measure in urolithiasis. World J Clin Urol 2017;6(2):40–3.
DOI: 10.5410/wjcu.v6.i2.40
Laube N., Hergarten S. Can the Bonn Risk Index be replaced by a simple measurement of the urinary concentration of free calcium ions? J Urol 2005;173(6):2175–7.
DOI: 10.1097/01.ju.0000158128.21188.ff
Gambaro G., Croppi E., Coe F. et al. Metabolic diagnosis and medical prevention of calcium nephrolithiasis and its systemic manifestations: a consensus statement. J Nephrol 2016;29(6):715–34.
DOI: 10.1007/s40620-016-0329-y
Williams J.C. Jr., Gambaro G., Rodgers A. et al. Urine and stone analysis for the investigation of the renal stone former: a consensus conference. Urolithiasis 2021;49(1):1–16.
DOI: 10.1007/s00240- 020-01217-3
Ganter K., Bongartz D., Hesse A. Tamm–Horsfall protein excretion and its relation to citrate in urine of stone-forming patients. Urology 1999;53(3):492–5.
DOI: 10.1016/s0090-4295(98)00581-0
Argade S., Chen T., Shaw T. et al. An evaluation of Tamm–Horsfall protein glycans in kidney stone formers using novel techniques. Urolithiasis 2015;43(4):303–12.
DOI: 10.1007/s00240-015-0775-3
Pourmand G., Nasseh H., Sarrafnejad A. et al. Comparison of urinary proteins in calcium stone formers and healthy individuals: a casecontrol study. Urol Int 2006;76(2):163–8.
DOI: 10.1159/000090882
Devuyst O., Olinger E., Rampoldi L. Uromodulin: from physiology to rare and complex kidney disorders. Nat Rev Nephrol 2017;13(9):525–44.
DOI: 10.1038/nrneph.2017.101
Micanovic R., LaFavers K., Garimella P.S. et al. Uromodulin (Tamm–Horsfall protein): guardian of urinary and systemic homeostasis. Nephrol Dial Transplant 2020;35(1):33–43.
DOI: 10.1093/ndt/gfy394
Wu J., Zhao J., Zhao Z. et al. Significance of TRPV5 and OPN biomarker levels in clinical diagnosis of patients with early urinary calculi. Am J Transl Res 2021;13(6):6778–83
Thamilselvan S., Khan S.R., Menon M. Oxalate and calcium oxalate mediated free radical toxicity in renal epithelial cells: effect of antioxidants. Urol Res 2003;31(1):3–9.
DOI: 10.1007/s00240-002-0286-x
Boonla C., Wunsuwan R., Tungsanga K., Tosukhowong P. Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 2007;35(4):185–91.
DOI: 10.1007/s00240-007-0098-0
Boonla C., Youngjermchan P., Pumpaisanchai S. et al. Lithogenic activity and clinical relevance of lipids extracted from urines and stones of nephrolithiasis patients. Urol Res 2011;39(1):9–19.
DOI: 10.1007/s00240-010-0281-6
Tsujihata M., Tsujikawa K., Tei N. et al. Urinary macromolecules and renal tubular cell protection from oxalate injury: comparison of normal subjects and recurrent stone formers. Int J Urol 2006;13(3):197–201.
DOI: 10.1111/j.1442-2042.2006.01271.x
el-Sharabasy M.M. Observations on calcium oxalate stone formers. Br J Urol 1992;70(5):474–7
Carrasco-Valiente J., Anglada-Curado F.J., Aguilar-Melero P. et al.. Actas Urol Esp 2012;36(5):296–301.
DOI: 10.1016/j.acuro.2011.08.004
Jung K., Kirschner P., Wille A., Brien G. Excretion of urinary enzymes after extracorporeal shock wave lithotripsy: a critical reevaluation. J Urol 1993;149(6):1409–13.
DOI: 10.1016/s0022-5347(17)36402-9
Голованов С.А., Синюхин В.Н., Ташлицкий В.А. и др. Экскреция триптофана, лизина, триметиллизина, саркозина, холина и 4-пиридоксиновой кислоты с мочой при мочекаменной болезни. Экспериментальная и клиническая урология 2022;15(1):68–75.
DOI: 10.29188/2222-8543-2022-15-1-68-75
Silverio A.A., Chung W.Y., Cheng C. et al. The potential of at-home prediction of the formation of urolithiasis by simple multi-frequency electrical conductivity of the urine and the comparison of its performance with urine ion-related indices, color and specific gravity. Urolithiasis 2016;44(2):127–34.
DOI: 10.1007/s00240-015-0812-2
Kavouras S.A., Suh H.G., Vallet M. et al. Urine osmolality predicts calcium-oxalate crystallization risk in patients with recurrent urolithiasis. Urolithiasis 2021;49(5):399–405.
DOI: 10.1007/s00240-020-01242-2
Tiselius H.G. Risk formulas in calcium oxalate urolithiasis. World J Urol 1997;15(3):176–185.
DOI: 10.1007/BF02201855
Kang H.W., Seo S.P., Ha Y.S. et al. Twenty-four-hour urine osmolality as a representative index of adequate hydration and a predictor of recurrence in patients with urolithiasis. Int Urol Nephrol 2019;51(7):1129–35.
DOI: 10.1007/s11255-019-02108-2
Shoag J., Eisner B.H. Relationship between C-reactive protein and kidney stone prevalence. J Urol 2014;191(2):372–5.
DOI: 10.1016/j.juro.2013.09.033
Mao W., Wu J., Zhang Z. et al. Neutrophil-lymphocyte ratio acts as a novel diagnostic biomarker for kidney stone prevalence and number of stones passed. Transl Androl Urol 2021;10(1):77–86.
DOI: 10.21037/tau-20-890
Kang H.W., Seo S.P., Kim W.T. et al. Hypertriglyceridemia is associated with increased risk for stone recurrence in patients with urolithiasis. Urology 2014;84(4):766–71.
DOI: 10.1016/j.urology.2014.06.013
Sonmez M.G., Kozanhan B., Deniz Ç.D. et al. Dynamic thiol/ disulfide homeostasis as a novel indicator of oxidative stress in patients with urolithiasis. Investig Clin Urol 2019;60(4):258–66.
DOI: 10.4111/icu.2019.60.4.258
Robert M., Boularan A.M., Delbos O. et al. Study of calcium oxalate crystalluria on renal and vesical urines in stone formers and normal subjects. Urol Int 1998;60(1):41–6.
DOI: 10.1159/000030201
Robertson W.G., Peacock M. Calcium oxalate crystalluria and inhibitors of crystallization in recurrent renal stone-formers. Clin Sci 1972;43(4):499–506.
DOI: 10.1042/cs0430499
Daudon M., Hennequin C., Boujelben G. et al. Serial crystalluria determination and the risk of recurrence in calcium stone formers. Kidney Int 2005;67(5):1934–43.
DOI: 10.1111/j.1523-1755.2005.00292.x
Frochot V., Daudon M. Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Int J Surg 2016;36(Pt D):624–32.
DOI: 10.1016/j.ijsu.2016.11.023
Arrabal-Polo M.A., Cano-Garcia M.D., Huerta-Brunel J.E. et al. Usefulness of measuring renal papillae in Hounsfield units in stone – forming patients. Int Braz J Urol 2016;42(5):973–6.
DOI: 10.1590/S1677-5538.IBJU.2015.0686
Shavit L., Girfoglio D., Kirkham A. et al. Increased renal papillary density in kidney stone formers detectable by CT scan is a potential marker of stone risk, but is unrelated to underlying hypercalciuria. Urolithiasis 2016;44(5):471–5.
DOI: 10.1007/s00240-016-0873-x
Ciudin A., Luque M.P., Salvador R. et al. Abdominal computed tomography – a new tool for predicting recurrent stone disease. J Endourol 2013;27(8):965–9.
DOI: 10.1089/end.2013.0161
Ciudin A., Luque M.P., Salvador R. et al. The evolution of CT diagnosed papillae tip microcalcifications: can we predict the development of stones? J Endourol 2014;28(8):1016–21.
DOI: 10.1089/end.2014.0151
Ferraro P.M., Vittori M., Macis G. et al. Changes in renal papillary density after hydration therapy in calcium stone formers. BMC Urol 2018;18(1):101.
DOI: 10.1186/s12894-018-0415-7
Kim S.C., Coe F.L., Tinmouth W.W. et al. Stone formation is proportional to papillary surface coverage by Randall’s plaque. J Urol 2005;173(1):117–9; discussion 119.
DOI: 10.1097/01.ju.0000147270.68481.ce
Strohmaier W.L., Hörmann M., Schubert G. Papillary calcifications: a new prognostic factor in idiopathic calcium oxalate urolithiasis. Urolithiasis 2013;41(6):475–9.
DOI: 10.1007/s00240-013-0606-3
Borofsky M.S., Paonessa J.E., Evan A.P. et al. A Proposed grading system to standardize the description of renal papillary appearance at the time of endoscopy in patients with nephrolithiasis. J Endourol 2016;30(1):122–7.
DOI: 10.1089/end.2015.0298
Almeras C., Pradere B., Estrade V., Meria P. Endoscopic papillary abnormalities and stone recognition (EPSR) during flexible ureteroscopy: a comprehensive review. J Clin Med 2021;10(13):2888.
DOI: 10.3390/jcm10132888
Berg W., Bechler R., Laube N. Analytical precision of the Urolizer for the determination of the BONN-Risk-Index (BRI) for calcium oxalate urolithiasis and evaluation of the influence of 24-h urine storage at moderate temperatures on BRI. Clin Chem Lab Med 2009;47(4):478–82.
DOI: 10.1515/CCLM.2009.099
Berg W., Bechler R., Haas C., Laube N. Relevance of the BONN Risk Index for metabolic monitoring of patients with calcium oxalate urolithiasis: a clinical application study of the Urolizer. Urol Res 2009;37(2):55–62.
DOI: 10.1007/s00240-009-0178-4
Grases F., Costa-Bauzá A., Prieto R.M. et al. Urinary lithogenesis risk tests: comparison of a commercial kit and a laboratory prototype test. Scand J Urol Nephrol 2011;45(5):312–8.
DOI: 10.3109/00365599.2011.584551
Erwin D.T., Kok D.J., Alam J et al. Calcium oxalate stone agglomeration reflects stone-forming activity: citrate inhibition depends on macromolecules larger than 30 kilodalton. Am J Kidney Dis 1994;24(6):893–900.
DOI: 10.1016/s0272-6386(12)81057-2
Lindberg J.S., Cole F.E., Romani W. et al. Calcium oxalate stone agglomeration inhibitionreflects renal stone-forming activity. Ochsner J 2000;2(2):68–78
Клочков В.B. Место «Литос-системы» в ранней диагностике, профилактике и лечении мочекаменной болезни. Медицинский альманах 2010;(4):242–4. Доступно по:https://cyberleninka.ru/article/n/mesto-litos-sistemy-v-ranney-diagnostike-profilaktike-i-lechenii-mochekamennoy-bolezni
Robertson W.G., Peacock M., Marshall R.W. et al. Saturation-inhibition index as a measure of the risk of calcium oxalate stone formation in the urinary tract. N Engl J Med 1976;294(5):249–52.
DOI: 10.1056/NEJM197601292940504
Pak C.Y., Galosy R.A. Propensity for spontaneous nucleation of calcium oxalate. Quantitative assessment by urinary FPR-APR discriminant score. Am J Med 1980;69(5):681–9.
DOI: 10.1016/0002-9343(80)90418-0
Pak C.Y., Galosy R.A. Propensity for spontaneous nucleation of calcium oxalate. Quantitative assessment by urinary FPR-APR discriminant score. Am J Med 1980;69(5):681–9.
DOI: 10.1016/0002-9343(80)90418-0